MicroCHIPS

Pioneering Applications in Biochemical Sensing: Diabetes
For the five million Americans with insulin-requiring diabetes (40 million worldwide), closely managing glucose levels is critical to avoiding the acute dangers of low blood sugar and the long term complications of prolonged hyperglycemia. MicroCHIPS' first product in development is a continuous sensing platform designed to transform how people with diabetes manage the condition.

MicroCHIPS' continuous glucose monitor will be a discreet, long-term implanted monitor designed to wirelessly deliver continuous, convenient, reliable and accurate glucose measurements. Sophisticated alerts and alarms will be designed to provide additional peace of mind and security — if glucose levels fluctuate beyond pre-set boundaries, alerts can warn the user, or his/her caregivers, of the condition.

This product under development will be the first in a series of intelligent medical devices on the path towards closed-loop monitoring and therapy systems that will deliver confidence and freedom to people with diabetes.

Continuous Glucose Monitoring Improves Glycemic Control in Adults with Type 1 Diabetes — A groundbreaking study, sponsored by the JDRF, recently published in the New England Journal of Medicine. Click here for the abstract

Driving Intelligent Drug Delivery: Osteoporosis
MicroCHIPS' drug delivery devices are being designed to deliver more effective drugs, allow fewer patient interventions, and assure compliance, all of which are essential in conditions ranging from cancer to infertility to osteoporosis. Our drug delivery platform offers the ability to store, protect, and precisely control the delivery of highly concentrated proteins and peptides. We use novel formulation techniques to create long-term drug stability and proprietary technology to protect our drug reservoirs.

MicroCHIPS' current drug delivery efforts are focused on the development and testing of a delivery device for PTH(1-34) for the treatment of osteoporosis. For the 200 million people world wide with osteoporosis, poor compliance with daily injections of anabolic agents limits their effectiveness. MicroCHIPS' delivery device under development has the potential to overcome the compliance limitations associated with injectable drug delivery.